Last reviewed · How we verify

NCT03632473: SMSC

Validation of Multimodal Evoked Potentials (mmEP) for Predicting Disease Progression in Multiple Sclerosis

Completed Last updated 19 September 2024
What this trial tests

trial testing multimodal evoked potentials (mmEP) in Multiple Sclerosis in 29 participants. Completed in 26 June 2020.

Timeline
28 August 2014
Primary endpoint
26 June 2020
26 June 2020

Quick facts

Lead sponsorUniversity Hospital, Basel, Switzerland
StatusCompleted
Study typeOBSERVATIONAL
Enrollment29
Start date28 August 2014
Primary completion26 June 2020
Estimated completion26 June 2020
Sites3 locations across Switzerland

Drugs / interventions tested

Conditions studied

Sponsor

University Hospital, Basel, Switzerland

Who can join

18 and older, any sex, with Multiple Sclerosis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Utility of Multimodal Evoked potentials (mmEP) for monitoring disease course and prediction of progression at different stages of Multiple Sclerosis (MS) is investigated

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Multiple Sclerosis

Currently open trials in the same condition.

Other University Hospital, Basel, Switzerland trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03632473.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing